PF-Atlas › Weekly Digest › For your doctor
Back to the weekly digest

A note for the treating physician

Your patient follows PF-Atlas, a free, independent research-intelligence project for idiopathic pulmonary fibrosis (IPF). It continuously scans ClinicalTrials.gov and PubMed and runs an in-silico drug-combination solver over existing, already-approved or already-studied drugs. The items below are computer-model hypotheses produced by that software. They are NOT clinical evidence, NOT an approved regimen, and NOT a recommendation to prescribe. Your patient is sharing this because they would value your clinical judgment.

What the model is currently exploring

Strongest simulated combination so far

In a 24-month in-silico model this combination of already-known drugs moved simulated lung function (FVC) toward about 99%. This is a model output, not a clinical result. Each component and its intended target:

  • WNT/RSPO3 agonist
  • ECM remodeling inhibitor
  • HOPX activator
  • Curcumin (TLR4/NLRP3)
  • miR-34a inhibitor
Repurposing candidates the solver flagged

Existing drugs the model suggests testing against IPF, with the biological bottleneck each is meant to address:

  • Inhaled GATA6 mRNA-LNP (Lipid Nanoparticle-formulated GATA6 mRNA for intratracheal delivery) · Intended to address: AEC2-to-AEC1 differentiation arrest: despite full AEC2 restoration (100%) and cleared ECM, the simulation plateaus at FVC 99.7% because mature AEC1 pneumocytes
    Inhalable LNP delivers GATA6 mRNA transiently to AEC2 progenitors. GATA6 protein binds AEC1-specific enhancers (AGER, PDPN, HOPX co-activation), suppresses SOX4-driven basaloid arrest, downregulates ID2 (which blocks AEC
  • CREB5 mRNA-LNP (Inhaled Lipid Nanoparticle) · Intended to address: AEC2-to-AEC1 differentiation arrest: despite maximal AEC2 restoration (100%) and ECM normalization (0% stiffness), FVC plateaus at 99.7% because newly generated
    Inhaled lipid nanoparticle delivery of synthetic CREB5 mRNA to AEC2 cells. CREB5 (cAMP Response Element Binding Protein 5) is a transcription factor identified in single-cell atlases as the master gate of AEC2→AEC1 termi
  • Inhaled NFIB mRNA-LNP (NF-IB Transcription Factor Restoration) · Intended to address: AEC2-to-AEC1 differentiation block: despite full AEC2 restoration (100%) and cleared ECM/senescence, FVC plateaus at ~99.7% because mature AEC1 pneumocytes (thi
    NFIB (Nuclear Factor I B) is a master transcriptional regulator of the AEC2→transitional→AEC1 differentiation continuum. It is required for HOPX+ transitional cell commitment to mature AEC1 fate, directly transactivating
  • TTF-1/NKX2-1 mRNA + SOX4 ASO Bifunctional LNP (Inhaled) · Intended to address: AEC2-to-AEC1 differentiation arrest: Despite maximal AEC2 restoration (100%) and ECM normalization (0% stiffness), FVC plateaus at 99.7% because mature AEC1 cel
    Inhaled lipid nanoparticle delivering (1) NKX2-1/TTF-1 synthetic mRNA to directly transcriptionally activate AEC1 fate genes (AGER, PDPN, AQP5, CAV1) and repress basaloid intermediacy, and (2) an antisense oligonucleotid
  • ETV5 Antisense Oligonucleotide (Inhaled) — ETV5-ASO · Intended to address: AEC2-to-AEC1 differentiation arrest: despite full AEC2 restoration (100%) and ECM normalization (0% stiffness), FVC plateaus at 99.7% because mature AEC1 pneumo
    ETV5 (ERM/PEA3-family transcription factor) is upregulated in IPF transitional AEC2 cells and actively suppresses the AEC2→AEC1 differentiation program by competing with NKX2-1 at AGER/PDPN/AQP5 promoters and by sustaini
  • FOXA2 mRNA-LNP (Inhaled Lipid Nanoparticle-Formulated FOXA2 Pioneer Factor mRNA) · Intended to address: AEC2-to-AEC1 differentiation arrest: despite full AEC2 replenishment (100%) and ECM normalization (0% stiffness), FVC plateaus at 99.7% because mature AEC1 pneu
    FOXA2 is the master pioneer transcription factor that (1) directly opens chromatin at HOPX, PDPN, and AQP5 loci to drive AEC2→AEC1 terminal differentiation, (2) transcriptionally represses SOX4 and TP63 to dissolve the b

How to read this

  • These are hypotheses from a computer model, generated to point research in useful directions. No human efficacy or safety data support them for IPF.
  • Any FVC or cell-level figures are simulation outputs over a mathematical model, not measured patient outcomes.
  • Some candidates are off-label or investigational and may carry real risks or interactions. Nothing here should change a treatment plan without your assessment.
  • Approved antifibrotics (pirfenidone, nintedanib) aim to slow decline, not reverse scarring. The model does not change that fact.

Sources your patient can review with you

New / updated trials
New studies
  • A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis. · Materials today. Bio 2026 PMID 43034868 on PubMed ↗
  • Pirfenidone exerts anti-inflammatory effects by inhibiting CXCL6 to alleviate idiopathic pulmonary fibrosis. · International immunopharmacology 2026 PMID 42759355 on PubMed ↗
  • Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axis. · Journal of ethnopharmacology 2026 PMID 42302945 on PubMed ↗
  • The Burden of Chronic Cough in Patients With Interstitial Lung Disease: a US Survey-Based Analysis of Its Effects on Daily Life and Emotional and Social Well-Being. · Chest 2026 PMID 43025804 on PubMed ↗
  • Overcoming the Pulmonary Mucus Barrier in Inhaled Drug Delivery: A Disease-Driven Precision Nanomedicine Framework. · Acta biomaterialia 2026 PMID 43025677 on PubMed ↗
  • Idiopathic pulmonary fibrosis: Five trials to watch. · Med (New York, N.Y.) 2026 PMID 43025400 on PubMed ↗
  • Idiopathic pleuroparenchymal fibroelastosis diagnosed following the onset of left vocal cord paralysis: A case report. · American journal of otolaryngology 2026 PMID 43025207 on PubMed ↗
  • Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 43021538 on PubMed ↗
  • Obstructive Sleep Apnea, Ferroptosis, and Idiopathic Pulmonary Fibrosis: A Potential Second-Hit Mechanism Linking Intermittent Hypoxia to Fibrotic Progression. · Respiratory medicine 2026 PMID 43020231 on PubMed ↗
  • Discovery of YKS-34, a Highly Selective PDE4B Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. · Journal of medicinal chemistry 2026 PMID 43018600 on PubMed ↗
  • Lung-Tailored Pyrrolo-pyrimidine DDR Inhibitors Designed for Optimized Local Delivery. · Journal of medicinal chemistry 2026 PMID 43018594 on PubMed ↗
  • Inhalable nanodelivery strategies for overcoming the pathological cascade of idiopathic pulmonary fibrosis. · International journal of pharmaceutics 2026 PMID 43014463 on PubMed ↗
  • Mesothelial plasticity regulates lung mechanical homeostasis in regeneration and fibrosis. · Developmental cell 2026 PMID 42914979 on PubMed ↗
  • Mechanism, Clinical Evidence, and Therapeutic Role of Nerandomilast in Fibrotic Lung Diseases. · Clinical drug investigation 2026 PMID 43009718 on PubMed ↗
  • Selective ORgan-targeting lipid nanoparticles deliver SMAD7 mRNA to fibrotic lungs and attenuate pulmonary fibrosis. · Journal of controlled release : official journal of the Controlled Release Society 2026 PMID 43009023 on PubMed ↗
  • RNA-binding proteins as emerging regulators in interstitial lung diseases. · American journal of respiratory cell and molecular biology 2026 PMID 43006853 on PubMed ↗
  • Targeting the Snail1-ATGL-ferroptosis-EMT axis via AKT-GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosis. · European journal of pharmacology 2026 PMID 42785459 on PubMed ↗
  • Pulmonary Fibroblast Heterogeneity and Functional Remodeling in Idiopathic Pulmonary Fibrosis: State Persistence and Reversibility. · International journal of molecular sciences 2026 PMID 43028275 on PubMed ↗
  • GPCRAgent: an intelligent multi-agent platform integrating knowledge graphs and large language models for GPCR-targeted drug discovery. · Journal of advanced research 2026 PMID 43003299 on PubMed ↗
  • Alive and on Initial Antifibrotic Treatment: Real-World Treatment Durability in Idiopathic and Progressive Pulmonary Fibrosis. · Journal of clinical medicine 2026 PMID 43030854 on PubMed ↗

Questions your patient would like to ask you

  • Are any of these mechanisms relevant to my case?
  • Is anything here already part of my care, or contraindicated for me?
  • Are there clinical trials I might be eligible for?
Medical disclaimer. PF-Atlas is an independent research-intelligence project. It is not a medical provider and does not give medical advice. This page summarizes computer-model hypotheses and public research for discussion with a qualified clinician. Verify everything against ClinicalTrials.gov, PubMed and your own clinical judgment before any decision.